Clinical trials: Coronary Arteriosclerosis
Myocardial Ischemia, Coronary Artery Stenosis
Safety Study of a Bioresorbable Coronary Stent
To evaluate the safety of a new bioresorbable (non-permanent) stent platform in native coronary arteries.
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- RESTORE (NCT01262703)
- Testing
- ReZolve Stent
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- REVA Medical, Inc.
Vasospastic Angina
Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina
This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of MFDS.
- Trial name
- STELLA_Ext (NCT02094469)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Coronary Artery Disease, Ischemic Heart Disease
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor : Resolute Onyx).
- Trial name
- NCT04562805
- Testing
- DynamX Bioadaptor, Resolute Onyx
- Where
- 19 sites in Sweden
- Volunteers
- 2,400 people
- Sponsor
- Elixir Medical Corporation
Coronary Disease, Coronary Arteriosclerosis
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary…
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
- Trial name
- ILLUSTRATE (NCT00134173)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 146 sites in United States, Belgium and 4 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Coronary Artery Disease
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.
- Trial name
- NCT00540670
- Testing
- E5555 50 mg, E5555 100 mg, E5555 200 mg
- Where
- 25 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Stable Angina, Unstable Angina
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal…
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEMONSTRATE (NCT01543373)
- Testing
- Amphilimus Eluting Stent, Bare Metal Stent
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 38 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Artery Disease (CAD)
BASel Kosten-Effektivitäts-Trial: Drug-coated BALLoon (DCB) vs. Drug-eluting Stent (DES) Strategy in High-risk Patients With Coronary Artery Disease (CAD)
The main objective of this randomized, multicenter, international, open-label clinical trial is to demonstrate that, in the context of percutaneous coronary intervention for complex coronary artery disease, a SeQuent® SCB…
- Trial name
- BASKET BALL (NCT07363161)
- Testing
- PCI
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 2,184 people
- Sponsor
- B. Braun Melsungen AG
Atherosclerosis
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days.
- Trial name
- NCT00411073
- Testing
- Darapladib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Angina Pectoris, Coronary Artery Disease
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
This study will evaluate the efficacy of ranolazine compared to placebo on duration of exercise assessed by exercise tolerance testing (ETT) at anticipated peak ranolazine plasma concentration after 12 weeks of treatment in…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT01334203
- Testing
- Ranolazine
- Sponsor
- Gilead Sciences
Cardiac Ischemia, Coronary Artery Disease
Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)
The Philips Angio-iFR medical software device is intended to provide information on the functional significance of a coronary artery lesion to provide guidance on diagnostic decisions similar to that obtained through invasive…
- Conditions
- Cardiac Ischemia, Coronary Artery Disease, Coronary Stenosis
- Trial name
- ReVEAL (NCT03857503)
- Testing
- iFR
- Where
- 40 sites in United States, Germany and 5 more
- Volunteers
- 441 people
- Sponsor
- Volcano Corporation
Heart Failure, Myocardial Ischemia
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy patients with angina is deleteriously affected by treatment with CK-1827452.
- Conditions
- Heart Failure, Myocardial Ischemia, Angina Pectoris
- Trial name
- NCT00682565
- Testing
- CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg capsule, CK-1827452 48 mg and 11 mg iv infusion
- Where
- 14 sites in Georgia, Russia
- Volunteers
- 94 people
- Sponsor
- Cytokinetics
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Angina Pectoris, Unstable Angina
Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization
The purpose of this study is to assess the safety and feasibility of a novel oxygen carrying solution, HBOC-201, in the setting of PCI for Acute Coronary Syndromes from randomization til hospital discharge.
- Conditions
- Angina Pectoris, Unstable Angina, Myocardial Infarction
- Trial name
- NCT00317512
- Testing
- Percutaneous Coronary Revascularization, Hemoglobin-Based Oxygen Carrier-201 (HBOC-201), Voluven
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 45 people
- Sponsor
- Biopure Corporation
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Coronary Artery Disease
Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent system in the treatment of patients with de novo coronary artery lesions.
- Trial name
- NCT02360709
- Testing
- CRE8 sirolimus-eluting stent
- Where
- China
- Volunteers
- 800 people
- Sponsor
- CID S.p.A.
Coronary Artery Disease
The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.
The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to the uncoated Bx…
- Trial name
- E-SIRIUS (NCT00235144)
- Testing
- sirolimus-coated Bx Velocity stent, uncoated Bx Velocity stent
- Where
- 2 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent
The objective of Series III Run-In Trial is to compare the performance and efficacy of the Supralimus® sirolimus-eluting stent with the Xience V™ everolimus-eluting stent with respect to in-stent luminal late loss at 9 months as…
- Trial name
- NCT00917163
- Testing
- Supralimus(R) Sirolimus-Eluting Coronary Stent System, Xience V™ Everolimus Eluting Coronary Stent
- Where
- 28 sites in Brazil, India and 1 more
- Volunteers
- 13 people
- Sponsor
- Sahajanand Medical Technologies Limited
Coronary Artery Disease
Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France
The objective of this study is to prepare elements of response to the Haute Autorité de Santé (High Health Authority) of France, which is expecting data relating to the routine use of XIENCE V® endoprothesis within the 5 years…
- Trial name
- Far XIENCE V® (NCT00987506)
- Testing
- XIENCE V®
- Where
- 58 sites in France
- Volunteers
- 1,165 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE-2 (NCT05918861)
- Testing
- Dalcetrapib
- Where
- 231 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- DalCor Pharmaceuticals
Chronic Stable Angina, Refractory Angina
Wave Crossover ECP Study for Simplified Therapy
The purpose of this study is to demonstrate substantial equivalence between Pression's Wave PRO System and a commercially available predicate ECP device to support a U.S. 510(k) submission for the Wave PRO System.
- Trial name
- WaveCRESST (NCT06571370)
- Testing
- External Counterpulsation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Pression